Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Unknown 3Completed 2Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Ovarian Neoplasms 1423Uterine Cervical Neoplasms 926Endometrial Neoplasms 493Carcinoma, Ovarian Epithelial 426Breast Neoplasms 425Fallopian Tube Neoplasms 413Neoplasms 274Uterine Cervical Dysplasia 208Colorectal Neoplasms 170Carcinoma, Non-Small-Cell Lung 168Pancreatic Neoplasms 156Prostatic Neoplasms 153Lung Neoplasms 151Stomach Neoplasms 126Peritoneal Neoplasms 119Sarcoma 117Uterine Neoplasms 112Melanoma 111Urinary Bladder Neoplasms 108Papillomavirus Infections 107Colonic Neoplasms 106Head and Neck Neoplasms 105Vulvar Neoplasms 101Esophageal Neoplasms 100Recurrence 95Testicular Neoplasms 91Carcinoma, Renal Cell 89Vaginal Neoplasms 79Small Cell Lung Carcinoma 77Kidney Neoplasms 74

Interventions

sintilimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Advanced Cervical Cancer × Gynecologic × Clear all
NCT04590599 2023-12-18

A Phase II Clinical Study to Assess the Efficacy and Safety of IBI310 or Placebo Combined With Sintilimab for Advanced Cervical Cancer Subjects Who Have Failed or Cannot Tolerate First-line or Above Platinum-based Chemotherapy

Innovent Biologics (Suzhou) Co. Ltd.

Phase 2 Completed
205 enrolled
Gynecologic

Advanced Cervical Cancer

NCT02888717 2020-03-24

GYNOSNA

Institut Cancerologie de l'Ouest

Phase NA Completed
16 enrolled
Gynecologic

Advanced Cervical Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡